Publications by authors named "J M Segura-Palacios"
Short-Term Effectiveness, Safety, and Potential Predictors of Response of Secukinumab in Patients with Severe Hidradenitis Suppurativa Refractory to Biologic Therapy: A Multicenter Observational Retrospective Study.
Pablo Fernandez-Crehuet Sofía Haselgruber Alicia Padial-Gomez Fiorella Vasquez-Chinchay Maria Dolores Fernandez-Ballesteros Juan Manuel Segura-Palacios
Dermatol Ther (Heidelb)
April 2023
Article Synopsis
- Hidradenitis suppurativa (HS) is a chronic skin condition, and secukinumab, a biologic drug, is being studied for its effectiveness and safety in treating moderate to severe cases over 16 weeks.
- A study involving 47 patients in southern Spain found that nearly 49% achieved significant clinical improvement (HiSCR) after treatment, with only a small percentage experiencing adverse effects.
- Factors such as being female, having a lower body mass index (BMI), and a lower previous treatment burden were linked to a higher likelihood of achieving the desired treatment response.
Ultrasound as a diagnostic and management tool in hidradenitis suppurativa patients: a multicentre study.
J Eur Acad Dermatol Venereol
November 2019
Background: It has been reported that clinical evaluation consistently underestimates the severity of hidradenitis suppurativa (HS).
Objective: To determine the usefulness of ultrasound as a diagnostic tool in HS compared with clinical examination and to assess the subsequent modification of disease management.
Methods: Cross-sectional multicentre study.